Intelligent Bio Solutions

INBS

Market cap $4.33M

Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites

Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Conference Details Date: June 16-18, 2026 Location: Bellagio Hotel & Casino, Las Vegas Presentation Date and Time: Wednesday, June 17, 2026, at 8:00 – 8:30 AM PDT Presentation Location: Track 7 – Donatello 3 Registration: Interested investors can register to attend here Webcast: Viewable here Booth: 413 The Company will be participating in one-on-one investor meetings throughout the event.

Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System  Company expects to complete enrollment and data collection by the end of July, 2026 NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. The Company has partnered with nationwide clinical research site network, CenExel Clinical Research, Inc., to perform the study, which will evaluate the accuracy of the Intelligent Fingerprinting Drug Screening System when operated by intended end-users across multiple clinical sites.

Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building on record first-half performance Gross profit margin expands to 50.5% in Q3 and 49.3% for the nine months, improving approximately 800 basis points year-over-year for the nine-month period NEW YORK, May 13, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal third quarter and nine months ended March 31, 2026, and provided a business update. "The third quarter marked another period of strong commercial execution and revenue growth," said Harry Simeonidis, President and CEO at INBS.

Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes

INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission

Study results finalized on schedule  support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference testing NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its initial clinical Cut-off Study supporting the Company's FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine. The clinical Cut-off Study evaluated codeine detection cut-off levels in 40 adults, with full data analysis completed as planned by the end of March 2026.

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received European Patent EP3752831, related to contextualizing fingerprint chemical analysis with fingerprint deposition volume. The grant marks the Company's eighth European patent, further enhancing intellectual property rights around its fingerprint sweat drug testing technology.

Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026